Bexarotene Patent Expiration
Bexarotene is Used for treating cutaneous lesions in patients with refractory or persistent stage IA and IB cutaneous T-cell lymphoma. It was first introduced by Valeant Pharmaceuticals Luxembourg Sarl
Bexarotene Patents
Given below is the list of patents protecting Bexarotene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Targretin | US5962731 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct 05, 2016
(Expired) | Bausch |
| Targretin | US5962731 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct 05, 2016
(Expired) | Valeant Luxembourg |
| Targretin | US5780676 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul 14, 2015
(Expired) | Bausch |
| Targretin | US5780676 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul 14, 2015
(Expired) | Valeant Luxembourg |
Bexarotene's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List